Last edition
News about "Luc Truyen"
argenx Updates Phase 3 UNITY Trial of Efgartigimod
argenx plans to stop its phase 3 UNITY study of efgartigimod SC in Sjögren’s disease following an IDMC recommendation based on interim analysis.
Luc Truyen | 09/10/2026 | By News Bureau
argenx Reports Positive Phase 3 ALKIVIA Results for Efgartigimod in Autoimmune Myositis
argenx reports positive Phase 3 ALKIVIA results for efgartigimod in autoimmune myositis, meeting the primary endpoint with sustained patient improvements.
Luc Truyen | 17/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy